Cited by 105Neonatal and Maternal InfectionsBacterial Infections and VaccinesStreptococcal Infections and Treatments

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27–28 April 2016

Open access
Kobayashi, Miwako, Schrag, Stephanie J., Alderson, Mark R., Madhi, Shabir A., Baker, Carol J., Sobanjo-ter Meulen, Ajoke, Kaslow, David C., Smith, Peter G. +2 more·2019·Vaccine

Abstract

Globally, group B Streptococcus (GBS) remains a leading cause of sepsis and meningitis in infants in the first 90days of life. Intrapartum antibiotic prophylaxis (IAP) for women at increased risk of transmitting GBS to their newborns has been effective in reducing part, but not all, of the GBS disease burden in many high income countries (HICs). In low- and middle-income countries (LMICs), IAP use is low. Immunization of pregnant women with a GBS vaccine represents an alternative strategy to protecting newborns and young infants, through transplacental antibody transfer and potentially by reducing new vaginal colonization. This vaccination strategy was first suggested in the 1970s and several potential GBS vaccines have completed phase I/II clinical trials. During the 2015 WHO Product Development for Vaccines Advisory Committee meeting, GBS was identified as a high priority for the development of a vaccine for maternal immunization because of the major public health burden posed by GBS in LMICs, and the high technical feasibility for successful development. Following this meeting, the first WHO technical consultation on GBS vaccines was held on the 27th and 28th of April 2016, to consider development pathways for such vaccines, focused on their potential role in reducing newborn and young infant deaths and possibly stillbirths in LMICs. Discussion topics included: (1) pathophysiology of disease; (2) current gaps in the knowledge of global disease burden and serotype distribution; (3) vaccine candidates under development; (4) design considerations for phase III trials; and (5) pathways to licensure, policy recommendations and use. Efforts to address gaps identified in each of these areas are needed to establish the public health need for, the development and deployment of, efficacious GBS vaccines. In particular, more work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2016.12.029

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Group B Streptococcus vaccines are currently in trials of maternal vaccination, with the aim of inducing maternal antibodies that cross the placenta and protect the newborn passively.

    “Group B Streptococcus vaccines are currently in trials of maternal vaccination, with the aim of inducing maternal antibodies that cross the placenta and protect the newborn passively118.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [14]World Health Organization. WHO recommendations for prevention and treatment of maternal peripartum infections. Geneva, Switzerland; 2015. 26598777
  2. [16]World Health Organization. Pocket book of hospital care for children: guidelines for the management of common childhood illness, 2nd ed.; 2013. 24006557

Cited by

Sorted by citations

Authors
Kobayashi, M., Schrag, S. J., Alderson, M. R., Madhi, S. A., Baker, C. J., Sobanjo-ter Meulen, A., Kaslow, D. C., Smith, P. G., Moorthy, V. S., & Vekemans, J.
Affiliations
  • Centers for Disease Control and Prevention (US)
  • Program for Appropriate Technology in Health (US)
  • University of the Witwatersrand (ZA)
  • Baylor College of Medicine (US)
  • London School of Hygiene & Tropical Medicine (GB)
  • World Health Organization (CH)
Corresponding author
Vekemans, Johan
Venue
Vaccine
Publisher
Elsevier BV
Published
2019-11
Volume
37
Issue
50
Pages
7307-7314
ISSN
0264-410X (ISSN-L)
OpenAlex
W2561215256
Cited by
105
References
55
Citations by year
2026: 6 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 11 · 2018: 15 · 2017: 10 · 2015: 1
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • Vaccine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • Lincoln (University of Nebraska) (submittedVersion, cc-by)
Funders
  • Novartis/GSK
  • Bill & Melinda Gates Foundation (OPP1134011)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Neonatal and Maternal Infections
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Streptococcal Infections and Treatments
Keywords
Streptococcus agalactiae, maternal immunization, intrapartum antibiotic prophylaxis, neonatal sepsis, neonatal meningitis, stillbirth, transplacental antibody transfer, serotype distribution, disease burden, correlates of protection, antibody assays, vaccine licensure, low- and middle-income countries
MeSH terms
Animals, Clinical Trials as Topic, Female, Humans, Pregnancy, Pregnancy Complications, Infectious, Streptococcal Infections, Streptococcus agalactiae, Vaccination, World Health Organization, Infectious Disease Transmission, Vertical, Streptococcal Vaccines, Stillbirth

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review